DBV Technologies downgraded to Sell from Neutral at Goldman Sachs

Goldman Sachs analyst Rajan Sharma downgraded DBV Technologies to Sell from Neutral with a price target of EUR 2, down from EUR 3. The analyst believes DBV’s lead asset, Viaskin Peanut, is a potential best-in-class therapeutic in the peanut allergy setting. Sharma added, however, that the timing of market entry and regulatory path forward is a key concern for the firm given the continued challenging development track record to date.